<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2013</study_start_year><condition>Neoplasm Metastasis</condition><condition>Carcinoma, Non-Small-Cell Lung</condition><condition>Melanoma</condition><condition>Colorectal Neoplasms</condition><condition>Neoplasms</condition><disease>Neoplasm Metastasis</disease><disease>Melanoma</disease><disease>Colorectal Neoplasms</disease><disease>Carcinoma, Non-small-cell Lung</disease><disease>Neoplasms</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2157084</full_dataset_link><location>United States</location><location>Australia</location><location>France</location><location>Spain</location><study_start_month>11</study_start_month><repository>ECRIN MDR</repository><study_status>Terminated</study_status></additional><is_claimable>false</is_claimable><name>A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body</name><description>The main purpose of this study is to see how safe the investigational drug known as LY3009120 is and whether it will work to help people with advanced cancer or cancer that has spread to other parts of the body.</description><dates><creation>2013-11-15</creation></dates><accession>2157084</accession><cross_references><ClinicalTrials___gov>NCT02014116</ClinicalTrials___gov></cross_references></HashMap>